Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Psilocybin 25mg Clear all
Active, not recruiting Phase 2 Interventional

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

NCT06206265
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
TRYP-0082, Psychotherapy
Drug · Behavioral
Lead sponsor
TRYP Therapeutics
Industry
Eligibility
21 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

NCT05399498
View directory record Official record
Conditions
Borderline Personality Disorder, Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

NCT04656301
View directory record Official record
Conditions
Body Dysmorphic Disorders
Interventions
Psilocybin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 18, 2026, 4:59 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

NCT05317689
View directory record Official record
Conditions
Healthy
Interventions
Psilocin, Psilocybin, Sublingual Psilocin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
25 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 3 Interventional

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Sharmin Ghaznavi
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 2 Interventional

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

NCT06888128
View directory record Official record
Conditions
PTSD
Interventions
Psilocybin 15mg, Psilocybin 25mg
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Early Phase 1 Interventional

Psilocybin as a Treatment for Chronic Pain in Smokers

NCT07118332
View directory record Official record
Conditions
Smokers With Chronic Pain
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

NCT04932434
View directory record Official record
Conditions
Parkinson Disease, Depression, Anxiety
Interventions
Psilocybin therapy
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Not listed Phase 2 Interventional

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

NCT04433858
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

RCT of Psilocybin-assisted CBT for Depression

NCT07281352
View directory record Official record
Conditions
Major Depressive Diorder
Interventions
Psilocybin (drug), cognitive behavioral therapy, Minimal supportive therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Psilocybin for PTSD

NCT06407635
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin, Trauma-focused psychotherapy, Standard psychological support
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Not listed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

NCT04593563
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Maryland Oncology Hematology, PA
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

NCT06626139
View directory record Official record
Conditions
Healthy Participants With Lower-than-average Mental Well-being
Interventions
Psilocybin, Context 1, Context 2, Placebo
Drug · Behavioral
Lead sponsor
Robin Carhart-Harris, PhD, MA
Other
Eligibility
21 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 1 Interventional

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

NCT05220046
View directory record Official record
Conditions
Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Psilocybin for Treatment-Resistant Depression

NCT06230757
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
Interventions
Psilocybin 25mg, Placebo (active placebo)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 1 Interventional

Psilocybin-assisted Therapy for Phantom Limb Pain

NCT05224336
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Psilocybin, Placebo Niacin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Withdrawn Phase 2 Interventional

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

NCT05381974
View directory record Official record
Conditions
Treatment-Resistant Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 18, 2026, 4:59 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

NCT07499583
View directory record Official record
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Not listed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for Intergenerational Trauma

NCT06899165
View directory record Official record
Conditions
Psychological Stress, Depression, Anxiety
Interventions
Psilocybin, Integration sessions
Drug · Behavioral
Lead sponsor
Rachel Yehuda
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Terminated Phase 1 Interventional

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT05322954
View directory record Official record
Conditions
Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Frontline Clinician Psilocybin Study

NCT05163496
View directory record Official record
Conditions
Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury
Interventions
Psilocybin (Usona Institute), Active placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 18, 2026, 4:59 AM EDT